Acting FDA Commissioner Sharpless Offers A Familiar List Of Priorities
Executive Summary
Many of Sharpless' priorities continue the work of his predecessor, but also are designed to make "immediate and significant impact."
You may also be interested in...
How Risky Is Amgen's At-Risk Launch Of Herceptin, Avastin Biosimilars?
In ongoing patent litigation with Genentech, Amgen may need to reveal its counsel's advice on whether it should launch, while Genentech must produce its settlement agreements with Mylan, Celltrion, and Pfizer.
Acting Normal: US FDA's Unusual Interim Period Drags On
The messaging around the US FDA commissioner transition has emphasized continuity and business-as-usual. But this is still all pretty weird.
Generic Drug Application Submission Downturn Continued In June
Approvals also plummeted, but US FDA remains on a record-breaking pace.